Profound Medicl (NYSE:PROF) – Analysts at Raymond James dropped their FY2019 EPS estimates for shares of Profound Medicl in a report released on Monday, January 27th. Raymond James analyst R. Sarugaser now expects that the company will post earnings of ($0.95) per share for the year, down from their prior estimate of ($0.24). Raymond James currently has a “Strong-Buy” rating on the stock. Raymond James also issued estimates for Profound Medicl’s Q1 2020 earnings at ($0.31) EPS, Q2 2020 earnings at ($0.33) EPS, Q3 2020 earnings at ($0.36) EPS, Q4 2020 earnings at ($0.33) EPS, FY2020 earnings at ($1.32) EPS, FY2021 earnings at ($1.19) EPS, FY2022 earnings at ($0.31) EPS and FY2023 earnings at $1.47 EPS.
Separately, Echelon Wealth Partners restated a “buy” rating on shares of Profound Medicl in a research report on Friday, November 8th.
Profound Medicl (NYSE:PROF) last posted its earnings results on Thursday, November 7th. The company reported ($0.43) EPS for the quarter. The firm had revenue of $0.52 million during the quarter.
About Profound Medicl
Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. It is developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids and nerves, and palliative pain treatment for patients with metastatic bone disease.
Featured Article: Inverted Yield Curve
Receive News & Ratings for Profound Medicl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medicl and related companies with MarketBeat.com's FREE daily email newsletter.
